Last reviewed · How we verify
NCT06956261
NW-301 TCR-T in Patients With Advanced Solid Tumor
Phase 1 trial testing NW-301V in Tumor, Solid in 44 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 10 May 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
| Sites | 2 locations across China |
Drugs / interventions tested
- NW-301V — full drug profile →
- Drug: NW-301D — full drug profile →
Conditions studied
- Tumor, Solid — all drugs for Tumor, Solid →
Sponsor
Peking University
Who can join
Adults 18 to 70, any sex, with Tumor, Solid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An open label, two cohorts, multiple dose exploratory clinical study to independently evaluate the safety, efficacy, and pharmacokinetics of autologous anti-KRAS G12V/G12D mutation T-cell Receptor T cell in advanced solid tumor
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06956261
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of NW-301V
Trials testing the same drug.
- NCT06484556 — T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid · Phase 1 · recruiting
- NCT06484790 — T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid · Phase 1 · recruiting
Other recruiting trials for Tumor, Solid
Currently open trials in the same condition.
- NCT07348042 — Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radic · Phase 1 · recruiting
- NCT06987500 — A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment · Phase 1, PHASE2 · recruiting
- NCT06911333 — AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07433283 — Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor · Phase 1, PHASE2 · recruiting
- NCT04723810 — TumorGlow Intraoperative Molecular Imaging (IMI) · Phase 1, PHASE2 · recruiting
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06956261 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 4 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06956261.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing